- Home
- IPDN vs CERO Comparison
IPDN vs CERO Comparison
Compare IPDN & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPDN
- CERO
- Stock Information
- Founded
- IPDN 2003
- CERO 2017
- Country
- IPDN United States
- CERO United States
- Employees
- IPDN N/A
- CERO N/A
- Industry
- IPDN EDP Services
- CERO
- Sector
- IPDN Technology
- CERO
- Exchange
- IPDN Nasdaq
- CERO Nasdaq
- Market Cap
- IPDN 4.3M
- CERO 3.5M
- IPO Year
- IPDN 2013
- CERO N/A
- Fundamental
- Price
- IPDN $2.18
- CERO $8.90
- Analyst Decision
- IPDN
- CERO Strong Buy
- Analyst Count
- IPDN 0
- CERO 2
- Target Price
- IPDN N/A
- CERO $45.00
- AVG Volume (30 Days)
- IPDN 2.9M
- CERO 3.3M
- Earning Date
- IPDN 08-12-2025
- CERO 08-13-2025
- Dividend Yield
- IPDN N/A
- CERO N/A
- EPS Growth
- IPDN N/A
- CERO N/A
- EPS
- IPDN N/A
- CERO N/A
- Revenue
- IPDN $6,508,349.00
- CERO N/A
- Revenue This Year
- IPDN N/A
- CERO N/A
- Revenue Next Year
- IPDN N/A
- CERO N/A
- P/E Ratio
- IPDN N/A
- CERO N/A
- Revenue Growth
- IPDN N/A
- CERO N/A
- 52 Week Low
- IPDN $0.97
- CERO $6.71
- 52 Week High
- IPDN $11.20
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- IPDN 58.07
- CERO 46.23
- Support Level
- IPDN $2.10
- CERO $8.50
- Resistance Level
- IPDN $3.30
- CERO $9.73
- Average True Range (ATR)
- IPDN 0.45
- CERO 1.20
- MACD
- IPDN 0.04
- CERO -0.01
- Stochastic Oscillator
- IPDN 30.56
- CERO 14.54
About IPDN Professional Diversity Network Inc.
Professional Diversity Network Inc is engaged in providing access to networking, training, educational and employment services to its registered users. It has three operating segments: the Professional Diversity Network (PDN) segment, which includes online professional networking communities with career resources for diverse cultural groups and employers looking to hire members; and the National Association of Professional Women (NAPW) segment, which is a women-only professional networking organization, the RemoteMore segment. The company generates majority of its revenue from PDN Segment.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.